Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Gustatory Dysfunction in Multiple Sclerosis
Teaching NeuroImages: MRI in advanced neuromyelitis optica.
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status
FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-β Production in Neurons.
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
Study hints of rituximab MS benefit
Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.
Acorda Therapeutics announces issuance of additional U.S. Patent for AMPYRA® covering a range of dosage strengths
HL-A antigens and multiple sclerosis.
The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α
Glatiramer acetate treatment negatively regulates type I interferon signaling.
CHMP adopts positive opinion for PLEGRIDY™ (peginterferon beta-1a) as a treatment for multiple sclerosis in the European Union
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.
Study to evaluate early glatiramer acetate treatment in delaying conversion to CDMS of subjects presenting with CIS (PreCISe)
BRIEF-Health Canada approves Genzyme's Aubagio to treat relapsing remitting multiple sclerosis
Mitoxantrone for multiple sclerosis.
A genome-wide association study of brain lesion distribution in multiple sclerosis.
Pharmacokinetic properties and metabolism of idebenone.
Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis.
Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain.
Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis
The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
URMC rheumatologist presents data showing drug’s potential to ease arthritis symptoms

Pages